Arteriogenesis - is this terminology necessary?

The role of the collateral circulation has been controversially discussed over many decades. With the availability of purified growth factors such as the fibroblast growth factors several studies provided data, that the growth of collateral arteries, termed arteriogenesis, is not limited to its natural timecourse. When applied in experimental models FGF in particular led to a significant increase in collateral conductance upon arterial occlusion.

GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function.

We investigated the role of the colony stimulating factor for monocytes (GM-CSF) to test the hypothesis whether prolongation of the monocyte's life cycle will support arteriogenesis (rapid growth of preexisting collateral arteries). This appeared logical in view of our discovery that circulating monocytes play an important part in the positive remodeling of small preexisting arterioles into arteries to compensate for arterial occlusions (arteriogenesis) and especially following our findings that MCP-1 markedly increases the speed of arteriogenesis. The continuous infusion of GM-CSF for 7 days into the proximal stump of the acutely occluded femoral artery of rabbits by osmotic minipump produced indeed a marked arteriogenic response as demonstrated by an increase (2-fold) in number and size of collateral arteries on postmortem angiograms and by the increase of maximal blood flow during vasodilation measured in vivo by blood pump perfusion of the hindquarter (5-fold).

Ehlers-Danlos syndrome type VI: lysyl hydroxylase deficiency due to a novel point mutation (W612C).

Ehlers-Danlos syndrome type VI (EDS VI) is a rare autosomal recessively inherited disease of connective tissue. The characteristic symptoms are hyperflexibility of joints and hyperelasticity of skin together with marked scoliosis, ocular manifestations and involvement of the vascular system. The underlying biochemical defect in EDS VI is a deficiency in lysyl hydroxylase (PLOD) activity resulting from mutations in the PLOD gene causing a low hydroxylysine content in various tissues.

The early pregnancy factor (EPF) in pregnancies of women with habitual abortions.

The EPF activity of 67 sera, obtained during the 6th to 9th week of pregnancy, was determined using the rosette inhibition test. The sera of uncomplicated pregnancies (n = 9) and of women with habitual abortions who came to delivery during the most recent pregnancy (n = 10) contained the highest EPF activity during the 6th week of gestation. When pregnancies ended in another abortion (n = 10) the EPF was never detected, or disappeared at least 1-2 weeks before abortion.